FDA orders new warning on GLP-1 drugs over potential risk of blindness
· Cairo time
The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must update their safety labelling to describe a possible link to permanent vision loss, the US Food and Drug Administration has said.The regulator said that it based the decision on research that linked a rare eye condition, called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause blindness, and Glucagon-like peptide-1 medication, which is used to…
